mazetx.com - MAZE Total Stockholders' Equity

Maze Therapeutics Inc (MAZE) delegates primary molecule testing to external CRO centers while maintaining full control over intellectual property. The business model is independent of economic cycles, relying instead on clinical trial results, with the metric standing at 0.45. The price trend clearly demonstrates the asset's dynamics. Maze Therapeutics Inc (MAZE) minimizes scientific risks through a personalized approach to the therapy of renal and metabolic pathologies.

GURU.Markets provides the book value for Maze Therapeutics Inc (MAZE), reflecting the company's intrinsic value. This metric captures the trend of net assets minus all liabilities. The calculation is based on the difference between the organization's total assets and its debts. In the biotech sector, this indicator determines the financial cushion available for clinical trials regardless of market cycles. Growth in this metric confirms the capital's resilience against potential write-downs.